Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 26.10.2021 at 12:00 PM CEST
Settings

Settings

Goto Application

1. WO2021207678 - KAPPA OPIOID RECEPTOR ANTAGONISTS FOR TREATING PAIN-RELATED SLEEP DISORDERS

Publication Number WO/2021/207678
Publication Date 14.10.2021
International Application No. PCT/US2021/026687
International Filing Date 09.04.2021
IPC
A61K 31/40 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
40having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 31/485 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
47Quinolines; Isoquinolines
485Morphinan derivatives, e.g. morphine, codeine
A61K 31/4709 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
47Quinolines; Isoquinolines
4709Non-condensed quinolines containing further heterocyclic rings
A61P 25/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
A61P 25/04 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
04Centrally acting analgesics, e.g. opioids
Applicants
  • ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA [US]/[US]
Inventors
  • PORRECA, Frank
  • ITO, Hisakatsu
  • NAVRATILOVA, Edita
Agents
  • NGUYEN, Quan
Priority Data
63/007,68609.04.2020US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) KAPPA OPIOID RECEPTOR ANTAGONISTS FOR TREATING PAIN-RELATED SLEEP DISORDERS
(FR) ANTAGONISTES DU RÉCEPTEUR OPIOÏDE KAPPA POUR LE TRAITEMENT DE TROUBLES DU SOMMEIL LIÉS À LA DOULEUR
Abstract
(EN)
Chronic pain patients complain about sleep disturbance with a high probability, while sleep loss increases pain in chronic pain patients. Sleep problems and pain promote a vicious spiral, suggesting a need for simultaneous treatment of both. The present invention provides a method to treat pain-related sleep disorders through distribution of a therapeutic amount of a KOR antagonist. The use of a KOR antagonist could be a novel therapeutic agent for sleep disturbance in chronic pain patients. Additionally, KOR antagonists could be used to improve sleep in other conditions, such as depression or general anxiety disorder, where KOR signaling is induced.
(FR)
Selon l'invention, les patients souffrant de douleur chronique se plaignent de troubles du sommeil avec une probabilité élevée, la perte de sommeil augmentant la douleur chez les patients souffrant de douleur chronique. Les problèmes de sommeil et la douleur favorisent un cercle vicieux, ce qui suggère un besoin de traitement simultané des deux. La présente invention concerne une méthode de traitement des troubles du sommeil liés à la douleur par la distribution d'une quantité thérapeutique d'un antagoniste de KOR. L'utilisation d'un antagoniste de KOR pourrait être un nouvel agent thérapeutique pour les troubles du sommeil chez les patients souffrant de douleur chronique. De plus, des antagonistes de KOR pourraient être utilisés pour améliorer le sommeil dans d'autres affections, telles que la dépression ou un trouble d'anxiété généralisée, où la signalisation KOR est induite.
Latest bibliographic data on file with the International Bureau